IBEX 35
10.870,70 -1,30 (-0,01%) Euro Stoxx 50
4.914,43 +23,82 (+0,49%) Dólar/Euro
1,0747 +0,0020 (+0,18%) Petróleo Brent
83,34 +0,31 (+0,37%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
55.202,83 +1.390,94 (+2,58%)
RUA Life Sciences plc (RUA.L)
RUA Life Sciences plc
2 Drummond Crescent
Irvine
KA11 5AN
United Kingdom
44 12 9431 7073
https://rualifesciences.com
Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 48
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. William Donald Brown | Executive Chairman | 266,98k | N/A | 1963 |
| Mr. Lachlan Arthur Smith | CFO & Director | 139k | N/A | 1980 |
| Mr. John McKenna | Director of Clinical Marketing & Executive Director | 73,78k | N/A | 1953 |
| Kathryn Mary Full FCCA | Company Secretary | N/A | N/A | N/A |
Descripción
RUA Life Sciences plc, together with its subsidiaries, engages in the provision of polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates through Biomaterials, Contract Manufacture, Vascular, and Structural Heart segments. The Biomaterials segment operates as depository of the Intellectual Property and licensing rights to a range of biostable and implantable polymers, including Elast-Eon and ECSil. The Contract Manufacture segment provides sub-contract manufacturing, assembly, packing and services to the medical device. The Vascular segment develops bore polymer sealed grafts and soft tissue patches. The Structural Heart segment manufactures synthetic heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Ayrshire, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de RUA Life Sciences plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
